SS-31 is a synthetic tetrapeptide designed to associate with cardiolipin on the inner mitochondrial membrane, making it one of the more deliberately engineered research peptides in the field.
Key Takeaways
- The sequence alternates aromatic and cationic residues, a pattern that promotes association with negatively charged cardiolipin without requiring a transporter.
- The peptide has progressed further than most research compounds, with studies in mitochondrial disease, heart failure, and ocular models.
- Because clinical data exist, claims about this peptide deserve a higher evidentiary bar than is usually applied in research-peptide discussions.
Design logic
The sequence alternates aromatic and cationic residues, a pattern that promotes association with negatively charged cardiolipin without requiring a transporter. The intent is to localise the peptide where reactive oxygen species generation is highest, rather than acting as a generic antioxidant.
Cardiolipin interaction
Cardiolipin is almost exclusive to the inner mitochondrial membrane and supports respiratory supercomplex assembly. Binding there is proposed to stabilise electron transport organisation, which is a more specific mechanism than scavenging radicals in bulk solution.
For related mechanism work, see Selank and Semax research.
Preclinical and clinical trajectory
The peptide has progressed further than most research compounds, with studies in mitochondrial disease, heart failure, and ocular models. This makes it unusual among laboratory peptides in having a genuine clinical literature, though results have been mixed across indications.
What the trials have shown
Several programmes have failed to meet primary endpoints despite encouraging early-phase signals. The gap between biomarker changes and functional outcomes is a recurring theme, and it is worth studying as a case in translational design.
Practical implications for reviewers
Because clinical data exist, claims about this peptide deserve a higher evidentiary bar than is usually applied in research-peptide discussions. Cite the trial record rather than the mechanistic rationale.
Experimental Conditions and Practical Setup
Mitochondrial studies typically isolate the organelle or use permeabilised cells, measuring oxygen consumption rate and membrane potential alongside cardiolipin content. Because the peptide associates with the inner membrane, preparation conditions that disrupt membrane integrity change the apparent result, and a respiratory-state-specific protocol is stated in advance.
Endpoints used in SS-31 studies
| Endpoint | What it reflects | Interpretation caution |
|---|---|---|
| Oxygen consumption rate | Respiratory chain function | State-specific; must define coupling state |
| Membrane potential | Inner membrane integrity | Sensitive to preparation quality |
| Cardiolipin content | Target engagement proxy | Does not prove functional benefit |
| Functional clinical outcome | Patient-relevant effect | Has diverged from biomarker changes in trials |
Practical Notes for the Bench
- Cite clinical endpoints rather than mechanistic rationale for this compound.
- Note cardiolipin localisation as the distinguishing design feature.
- Separate biomarker shifts from functional outcomes when reviewing trials.
Frequently Asked Questions
How does SS-31 reach the mitochondria?
Its alternating aromatic-cationic motif drives association with cardiolipin on the inner membrane without a specific transporter.
Has it been tested in humans?
Yes, unlike most research peptides it has a real clinical trial record across several indications, with mixed results.
Is it simply an antioxidant?
No. The intended mechanism is membrane-localised stabilisation of respiratory complexes rather than bulk radical scavenging.
Why do biomarker improvements not translate into clinical benefit?
Because biomarker change and functional improvement are different questions. In this class, trials have repeatedly shown biomarker movement without meeting primary functional endpoints.
Related Reading
- Selank and Semax research
- KPV anti-inflammatory peptide
- GHK-Cu copper peptide
- transdermal peptide delivery
- peptide aggregation detection
References & Further Reading
- Zhao W et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019. PubMed 31747905
- Zheng H et al. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomed Pharmacother. 2025. PubMed 39848110
- Nie Y et al. Elamipretide(SS-31) Attenuates Idiopathic Pulmonary Fibrosis by Inhibiting the Nrf2-Dependent NLRP3 Inflammasome in Macrophages. Antioxidants (Basel). 2023. PubMed 38136142
- Peptide literature search on PubMed
- Full-text archive at PubMed Central
- Peptide research collection at Nature
All material on this page is intended for laboratory research and educational reference only. It is not medical advice, and it does not describe any approved diagnostic or therapeutic use.
Reviewed by Priya Raghunathan, MSc, Formulation & Stability Science.